None listed
Conditions
Brief summary
A 2-Part, Single-Dose Study to Evaluate the Interaction of Etoricoxib and Tizanidine MR when Co-administered or Administered Alone in Healthy Subjects MK0663B (combination treatment) is being developed for the treatment of acute pain in musculoskeletal conditions with swelling and muscle spasm. However, this study is in healthy volunteers only.
Interventions
Treatment A: Co-administration of a single oral dose of etoricoxib 90mg (tablet) and tizanidine MR 6mg (capsule)
Treatment B: Administration of a single oral dose of etoricoxib 90mg (tablet) alone
Treatment C: Administration of a single oral dose of tizanidine MR 6mg (capsule) alone
All participants will receive single oral doses of each treatment in a 3 way crossover fashion with a minimum of 7 day washout period in between.
MK0663B (combination treatment) is being developed for the treatm
Treatment A: Co-administration of a single oral dose of etoricoxib 90mg (tablet) and tizanidine MR 6mg (capsule) Treatment B: Administration of a single oral dose of etoricoxib 90mg (tablet) alone Treatment C: Administration of a single oral dose of tizanidine MR 6mg (capsule) alone All participants will receive single oral doses of each treatment in a 3 way crossover fashion with a minimum of 7 day washout period in between. MK0663B (combination treatment) is being developed for the treatment of acute pain in musculoskeletal conditions with swelling and muscle spasm. However, this study is in healthy volunteers only.
Sponsors
Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
-BMI < 30kg/m2 -Female of reproductive potential to have -negative pregnancy test and agree to use double-barrier contraception -Good health based on medical history, physical examination, vital sign measurements, ECG and laboratory assessments -Non smoker
Exclusion criteria
History of emotional problems or clinically significant psychiatric disorder within 5yrs -Clinically significant disease/disorder of any body systems -Creatinine clearance of <80mL/min -History of neoplastic disease -Breast feeding mother -History of stroke, chronic seizures or major neurological disorder -Current use of prescription/non-prescription medication -Consumes excessive amounts of alcohol -Consumes excessive amounts of caffeine -History of significant or severe allergies or anaphylactic reaction -History of serious adverse experiences related to non-steroidal anti-inflammatory drug -Regular user of illicit drugs
Outcome results
None listed